Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

PURPOSE: Higher doses of cytarabine appear to improve long-term outcome in acute myeloid leukemia (AML), in particular for younger patients. To this end, the optimal dosage of single-agent cytarabine in consolidation therapy remains elusive. Here, we assessed the impact of different dosages of cytar...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanoun, Maher, Ruhnke, Leo, Kramer, Michael, Hanoun, Christine, Schäfer-Eckart, Kerstin, Steffen, Björn, Sauer, Tim, Krause, Stefan W., Schliemann, Christoph, Mikesch, Jan-Henrik, Kaufmann, Martin, Hänel, Mathias, Jost, Edgar, Brümmendorf, Tim H., Fransecky, Lars, Kraus, Sabrina, Einsele, Hermann, Niemann, Dirk, Neubauer, Andreas, Kullmer, Johannes, Seggewiss-Bernhard, Ruth, Görner, Martin, Held, Gerhard, Kaiser, Ulrich, Scholl, Sebastian, Hochhaus, Andreas, Reinhardt, H. Christian, Platzbecker, Uwe, Baldus, Claudia D., Müller-Tidow, Carsten, Bornhäuser, Martin, Serve, Hubert, Röllig, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349710/
https://www.ncbi.nlm.nih.gov/pubmed/36167894
http://dx.doi.org/10.1007/s00432-022-04356-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349710/
https://www.ncbi.nlm.nih.gov/pubmed/36167894
http://dx.doi.org/10.1007/s00432-022-04356-9

Ejemplares similares